Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to reach US$ 5.26 billion by 2031

Metformin Segment to Hold Significant Share of Polycystic Ovarian Syndrome (PCOS) Treatment Market During 2023–2031

According to our latest study on "Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecast to 2031 – Global Analysis – Product, and Distribution Channel," the market is expected to reach US$ 5.26 billion by 2031 from US$ 3.46 billion in 2023; it is estimated to record a CAGR of 5.4% during 2023–2031. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the increasing prevalence of polycystic ovary syndrome (PCOS) among women globally and rising government initiatives and support for research in the field of reproductive health propel the Polycystic Ovarian Syndrome (PCOS) Treatment Market growth. However, the limited availability of FDA-approved medications specifically for PCOS restrains the market growth. The integration of artificial intelligence (AI) and machine learning (ML) in PCOS diagnosis and treatment is expected to bring new polycystic ovarian syndrome (PCOS) treatment market trends during the forecast period.

Governments across the world are recognizing the growing prevalence of PCOS and the impact of the condition on women's health, fertility, and overall well-being, leading to increased funding and resources dedicated to research and treatment initiatives. Government support for research in PCOS treatment plays a crucial role in driving advancements in personalized medicine and precision healthcare. By funding studies that investigate the genetic, hormonal, and metabolic factors underlying PCOS, governments are helping to identify targeted therapies that can address the specific needs of individual patients. The government of India, through the Indian Council of Medical Research (ICMR), launched a large-scale representative country-wide epidemiological multicentric study on PCOS. Similarly, the US passed a resolution that recognizes the importance of PCOS treatment and designated September 2021 as "PCOS Awareness Month". Moreover, government initiatives are instrumental in promoting interdisciplinary collaboration among healthcare providers, researchers, policymakers, and patient advocacy groups. By fostering partnerships and knowledge-sharing across different sectors, governments can create a holistic approach to managing PCOS that addresses the physical symptoms and psychological aspects of the condition. Thus, the increasing government initiatives and support for research in the field of reproductive health fuel the polycystic ovarian syndrome (PCOS) treatment market growth.

Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Geography, 2023 (%)

Source: The Insight Partners Analysis

India, China, Argentina, Brazil, the UAE, South Africa, and other emerging countries are expected to offer significant opportunities for the polycystic ovarian syndrome (PCOS) treatment market players due to rising disposable incomes, upsurging PCOS patient population, increasing R&D activities, improving healthcare infrastructure, growing disease awareness, and relatively lenient guidelines compared to developed countries. Furthermore, the governments of these countries are focusing on increasing access to effective and cutting-edge healthcare services for a larger proportion of their populations and improving reimbursement coverage. The expansion of healthcare products across these nations is driven by the quick increase in per-capita healthcare spending and rise in public demand for affordable healthcare services. According to the World Economic Forum, as of 2022, Russia, Brazil, China, India, and South Africa collectively accounted for a third of global health spending. As per the World Bank, health spending in India and China increased by 3.01% and 5.35%, respectively, from 2018 to 2019. Thus, the increasing healthcare expenditure in emerging countries is likely to provide opportunities for the polycystic ovarian syndrome (PCOS) treatment market during the forecast period.

The “polycystic ovarian syndrome (PCOS) treatment market analysis” has been carried out by considering the following segments: product and distribution channel. By product, the market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held the largest market share in 2023. The clomiphene citrate segment is anticipated to register the highest CAGR during the forecast period. The market, based on distribution channel, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023 and is anticipated to register the highest CAGR during the forecast period.

Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Geography:

The geographic scope of the polycystic ovarian syndrome (PCOS) treatment market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

In 2023, North America held the largest polycystic ovarian syndrome (PCOS) treatment market share. The growing adoption of the latest medical device technologies, high prevalence of PCOS, and rising product innovations by key players contribute to the increasing polycystic ovarian syndrome (PCOS) treatment market size in North America. Asia Pacific is expected to record the highest CAGR during the forecast period owing to the increasing number of PCOS patients and rising healthcare expenditure in major countries in the region.

The polycystic ovarian syndrome (PCOS) treatment market report emphasizes key developments by prominent players. Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc are among the prominent players in the polycystic ovarian syndrome (PCOS) treatment market. These companies have been implementing various strategies that contribute to their growth and lead to various changes in the market. Organic strategies implemented by them include product launches, expansions, and product approvals, whereas inorganic strategies include collaborations and partnerships.

A few of the recent developments in the global market, as per the company press releases, are mentioned below:

• In December 2021, Organon announced the acquisition of Forendo Pharma, a clinical-stage drug development company focusing on novel treatments for women’s health. FOR-6219, Forendo's main product, is an experimental, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor entering Phase 2 clinical research for endometriosis. Forendo's pipeline also includes preclinical research aimed at PCOS.
• In January 2020, Evotec SE and Bayer AG expanded their partnership with a new five-year, multi-target collaboration to develop various clinical candidates for treating PCOS. According to the agreement, both firms were responsible for contributing medication targets and a comprehensive set of high-quality technology platforms to collaborate on the development of breakthrough treatment options.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com